JNJ-42756493, GEMCITABINE , MITOMYCIN
42756493BLC3004
Phase 3 small_molecule active
Quick answer
JNJ-42756493, GEMCITABINE , MITOMYCIN for FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active